Program
nuvisertib
Also written as “TP-3654”, “Nusivertib” and “TP 3654”.
Its studies are mostly in Primary Myelofibrosis · Neoplasms, led by Sumitomo Pharma.
Furthest: phase 2, since Nov 8, 20194 company-led studies, 1 open or runningNext primary completion: Apr 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sumitomo Pharma | 41 open or running | phase 2since Nov 8, 2019 | Oct 19, 2018 | Apr 30, 2027phase 2 · NCT04176198 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 19, 2018First study: phase 1 study in NeoplasmsFirst studyNCT03715504 · 22 enrolled · United States
- Nov 8, 2019Phase 2 study in Primary MyelofibrosisNCT04176198 · 240 planned · United States, Australia, Belgium and more
- Apr 22, 2024Phase 1 study in HealthyNCT06389955 · 12 enrolled · United States
- Mar 19, 2026Phase 1 study in Primary MyelofibrosisNCT07492355 · 24 enrolled · United States
Ahead
- Apr 30, 2027Primary completion: phase 2 study in Primary MyelofibrosisNCT04176198
TargetBeta
PIM1 →read by rule
“An orally available, second-generation and selective ATP-competitive inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases, ”NCIt, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07492355Primary Myelofibrosis · United States | 1 | Completed | May 31, 2024 | 24 |
| NCT06389955Healthy · United States | 1 | Completed | Aug 1, 2023 | 12 |
| NCT04176198Primary Myelofibrosis · United States, Australia, Belgium and more | 2 | Recruiting | Apr 30, 2027 | 240 |
| NCT03715504Neoplasms · United States | 1 | Completed | Mar 30, 2021 | 22 |
How it is read
Names in the registry
- “TP-3654”, 2 entries
- “Nusivertib”, 1 entry
- “TP 3654”, 1 entry
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 2 studies
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.